1[1]Wingate D, Hongo M, Kellow J, et al. Working party report.Disorders of gastrointestinal motility: Towards a new classification.J of Gastroenterology and Hepatology, 2002, 17 (Suppl.):S1 ～S14
2[3]American Gastroenterology Association medical position statement: irritable bowel syndrome. Gastroenterology, 2002, 123(6): 2105 ～2107
3[4]Drossman DA, Camillei M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123(6): 2108～2131
4[5]Akehurst R, Kaltenthaler E.Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut, 2001, 48(2): 272～282
5[6]Coelho AM, Rovira P, Fioramonti J, et al. Antinociceptive properties of HTF 919 (tegaserod) , a 5-HT4 receptor partial agonist, on colorectal distension in rats. Gastroenterology,2000, 118:A835
6[7]Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil, 2002, 14:221 ～ 227
7[8]Wagstaff AJ, Frampton JE, Croom KF, et al. Tegaserod a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs, 2003, 63 (11): 1101 ～ 1120
8[9]Dunger-Baldauf C, Rueegg PC, Lefkowitz M. Is relief from abdominal discomforort/pain in tegaserod treated IBS-C patients due to an increased frequency of bowel movements? Am J Gastroenterol, 2002, 97 (9 suppl.): S275
9[10]Grundy D. Towards a reduction of rectal pain? Neurogastroenterol Mot, 2002, 14: 217～219
10[11]Poen AC, Felt-Bersma RJ, Van-Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment PharmacolTher, 1999, 13 (11): 1493～1497
二级参考文献10
1Williama CL,Villar RG, Peterson JM, et al. Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome.Gastroenterology, 1988,94 : 611-621.
2Nagasaki M, kobayashi T, Tamaki H. Effects of trimebutine on cytosolic Ca^2 + and force transitions in intestinal smooth muscle. Eur J Pharmacol, 1991,195:317-321.
3Nagasaki M, Komari S, Tamaki H, et al. Effect of trimebutine on K^+ current in rabbit ileal smooth muscle cells. Eur J Pharmacol,1993,235 : 197-203.
4Nagasaki M, Komari S, Ohashi H, et al. Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells.Br J Pharmacol, 1993,110:399-403.
5Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J lnt Med Res,1997, 25:225-246.
6Godfraind T, Miller R, Wibo M, et al. Calcium antagonism and calcium entry blockade. Pharmacol Rev, 1996,38:321-416.
